查找临床试验
已按「IgA 肾病」检索，对应国际通用词 IgA nephropathy
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:18，每 5 分钟自动同步Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
United States、Argentina、Australia、Canada、Malaysia 等 9 国
年龄 18 Years – 100 Years
Novartis Pharmaceuticals
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
China
年龄 18 Years – 不限
Haisco Pharmaceutical Group Co., Ltd.
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
United States、Argentina、Australia、Belgium、Brazil 等 12 国
年龄 18 Years – 不限
Biogen
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
China
年龄 3 Years – 不限
The Children's Hospital of Zhejiang University School of Medicine
Chinese Adults With Kidney Disease
China
年龄 18 Years – 不限
ADARx Pharmaceuticals, Inc.
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
China
年龄 18 Years – 不限
Chengdu Suncadia Medicine Co., Ltd.
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
China
年龄 18 Years – 65 Years
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
United States、Australia、Hong Kong、Italy、South Korea 等 8 国
年龄 18 Years – 不限
ADARx Pharmaceuticals, Inc.
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
China
年龄 18 Years – 75 Years
Nanfang Hospital, Southern Medical University
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
United States、China、Japan、South Korea
年龄 2 Years – 18 Years
Novartis Pharmaceuticals
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
China
年龄 14 Years – 不限
Sun Yat-sen University
Efficacy and Safety of Telitacicept in IgAN
China
年龄 18 Years – 70 Years
Ruijin Hospital